Endocrine therapy remains the cornerstone of systemic treatment in male breast cancer due to the overwhelmingly high prevalence of hormone receptor positivity, a pattern consistently observed across multiple studies including our own cohort, in which nearly 90% of evaluable patients were ER-positive. The gene discussed is NR4A1; the disease is male breast carcinoma.